336 related articles for article (PubMed ID: 11549514)
1. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
Salih HR; Nüssler V
Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
[TBL] [Abstract][Full Text] [Related]
2. [The relationship between immunological defence and the development of tumours].
Leone G
Arch Sci Med (Torino); 1973; 130(4):273-82. PubMed ID: 17343168
[TBL] [Abstract][Full Text] [Related]
3. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
Kourilsky P; Jaulin C; Ley V
Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
[TBL] [Abstract][Full Text] [Related]
4. Escape mechanisms in tumor immunity: an update.
Müller L; Kiessling R; Rees RC; Pawelec G
J Environ Pathol Toxicol Oncol; 2002; 21(4):277-330. PubMed ID: 12510961
[TBL] [Abstract][Full Text] [Related]
5. MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors.
Ward PL; Schreiber H
Semin Cancer Biol; 1991 Oct; 2(5):321-8. PubMed ID: 1837738
[TBL] [Abstract][Full Text] [Related]
6. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
7. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
8. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
Marincola FM; Jaffee EM; Hicklin DJ; Ferrone S
Adv Immunol; 2000; 74():181-273. PubMed ID: 10605607
[No Abstract] [Full Text] [Related]
9. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
10. [Tumor-induced immunosuppression].
Paul S; Calmels B; Régulier E
Ann Biol Clin (Paris); 2002; 60(2):143-52. PubMed ID: 11937439
[TBL] [Abstract][Full Text] [Related]
11. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
12. The flip side of immune surveillance: immune dependency.
Prehn RT; Prehn LM
Immunol Rev; 2008 Apr; 222():341-56. PubMed ID: 18364013
[TBL] [Abstract][Full Text] [Related]
13. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance.
Chang CC; Ferrone S
Semin Cancer Biol; 2006 Oct; 16(5):383-92. PubMed ID: 16931041
[TBL] [Abstract][Full Text] [Related]
14. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.
Mapara MY; Sykes M
J Clin Oncol; 2004 Mar; 22(6):1136-51. PubMed ID: 15020616
[TBL] [Abstract][Full Text] [Related]
15. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
16. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
17. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
18. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
Hamaï A; Benlalam H; Meslin F; Hasmim M; Carré T; Akalay I; Janji B; Berchem G; Noman MZ; Chouaib S
Tissue Antigens; 2010 Jan; 75(1):1-8. PubMed ID: 20196816
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment and immune escape.
Ferrone S; Whiteside TL
Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
[TBL] [Abstract][Full Text] [Related]
20. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
